A patient with primary Sjögren's syndrome developed massive gland enlargement and was diagnosed a MALTtype lymphoma stage IIA. After initial radiotherapy the patient relapsed with high grade immunoblastic lymphoma. Chemotherapy led to remission of the lymphoma and improvement of the autoimmune disease. A peripheral blood stem cell harvest was performed. However, subsequent to standard chemotherapy the patient experienced an exacerbation of arthralgia and vasculitis while his lymphoma remained in partial remission. With additional chemotherapy and steroid treatment complete remission of the lymphoma and autoimmune disease was achieved and high-dose chemotherapy followed by PBPCT with an unmanipulated graft was performed. Engraftment was prompt with no signs of active autoimmune disease after the transplantation. Two months later, signs of autoimmune disease slowly recurred. Steroid treatment improved this, but the patient remained steroid-dependent and later died from therapy-resistant Pneumocystis carinii pneumonia while the lymphoma remained in complete remission. In this patient with systemic Sjögren's disease, PBPCT completely controlled the aggressive lymphoma but was not permanently effective for the autoimmune disease.
increasing interest in the use of high-dose chemotherapy with autologous progenitor cell support for the treatment of autoimmune diseases. While formal pilot studies are being initiated, our experience is currently based on case reports of progenitor cell transplants in patients with hematological diseases and concomitant autoimmune disorders. [8] [9] [10] To our knowledge there has been no report on the effect of highdose chemotherapy and autologous stem cell transplantation in primary Sjögren's syndrome. This disease usually presents as a chronic, slowly progressive autoimmune process of unknown origin. The typical symptoms include keratoconjunctivitis sicca and xerostomia due to involvement of lacrimal and salivary glands. However, the disease may develop into a systemic disorder with involvement of kidneys, lung, muscles and blood vessels, usually accompanied by various autoantibodies. These include antinuclear antibodies, anti-La, anti-Ro, rheumatoid factor and cryoglobulins. Finally, evolution of a B cell lymphoproliferative disorder is possible which may be confined to salivary and lacrimal glands, but may also involve lymph nodes, bone marrow, gastrointestinal tract and other organs. Here, we report the case of a patient with primary Sjögren's syndrome who developed a lymphoma which, after relapse, was treated by an autologous peripheral blood progenitor cell transplantation (PBPCT).
Case report
A 33-year-old woman with xerostomia, keratoconjunctivitis sicca and facial swelling was diagnosed with primary Sjög-ren's syndrome, involving both parotid glands (Figure 1 ). Diagnosis was confirmed by biopsy. Due to massive gland enlargement developing 1 year later, a right-sided parotidectomy was performed which led to the diagnosis of lowgrade lymphoma, MALT-type, stage IIA. At that time the patient showed signs of active systemic Sjögren's disease with palpable vasculitic purpura and arthralgia. Serological signs of autoimmune disease were found, namely rheumatoid factor, low complement levels, anti-Ro, anti-La and an elevated CRP and beta-2-microglobulin.
The lymphoma was irradiated, but relapsed 6 month later. At this time aggressive immunoblastic lymphoma of B cell origin with involvement of the stomach and lymph nodes on both sides of the diaphragm was found. Moreover, vasculitic purpura accompanied by peripheral neuropathy was present. Chemotherapy with VACOP-B 11 followed by intensive VIPE 12 chemotherapy, consisting of etoposide, ifosfamide, cisplatinum and epirubicin, led to remission of lymphoma and to a marked improvement of the patient's autoimmune disease. No corticosteroids were given concomitantly. Following VIPE chemotherapy and G-CSF mobilization (5 g/kg × day s.c.) a peripheral blood progenitor cell harvest was performed, using a Cobe spectra cell processor (Cobe BCT, Lakewood, CO, USA).
However, after the second cycle of VIPE chemotherapy the patient experienced an exacerbation of her arthralgia and vasculitis with purpura, while the lymphoma remained in good partial remission. At this time, high titers of rheumatoid factor indicated active autoimmune disease. Complete remission of lymphoma and autoimmune disease was achieved with one additional VIP chemotherapy and concomitant steroid treatment.
High-dose therapy with BEAM 13 was initiated, followed by an unmanipulated peripheral blood progenitor cell graft. (37.03 × 10 6 /kg), respectively. Engraftment was uneventful with leukocytes above 1000/l on day 11 and platelets above 50 000/l on day 18. While initially the lymphoma and Sjögren's syndrome were in complete remission, 2 months later thrombocytopenia developed and serological signs of active autoimmune disease recurred, followed shortly thereafter by arthralgia, vasculitic purpura and a capillary leak-like swelling of the face. Repeated CAT scans and bone marrow biopsies excluded recurrent lymphoma as the cause of the thrombocytopenia and rheumatologic symptoms. No lymphocytic infiltration of the bone marrow could be found and megakaryopoiesis was normal. However, there was a predominance of activated Ia-positive T cells in the mononuclear fraction of the patient's peripheral blood and bone marrow.
Initiation of steroid treatment was necessary and the serological and clinical signs of Sjögren's disease improved, including normalization of the platelet count. However, the patient remained steroid dependent with vasculitis recurring after each attempt to decrease the steroid doses below a threshold level of about 20 mg of prednisone. With continued immunosuppressive treatment she acquired a therapy-resistant Pneumocystis carinii pneumonia and died 20 months after the transplantation while the lymphoma was still in complete remission.
In this particular case, activity of the Sjögren's syndrome was best reflected by the titer of rheumatoid factor, while complement levels, CRP, and beta-2-microglobulin were less informative. Antinuclear antibodies, anti-Ro and antiLa, though periodically elevated, were not associated with clinical severity of the disease.
Discussion
We report the first case of a patient with systemic Sjögren's syndrome, who underwent high-dose chemotherapy with unmanipulated autologous progenitor cell transplantation. The indication for this treatment was not the autoimmune disease, but rather the concomitant development of relapsing aggressive lymphoma. Induction chemotherapy led to a marked improvement in the autoimmune disease, and after high-dose chemotherapy complete remission not only of the lymphoma but also of the autoimmune disease was achieved. However, remission of Sjögren's syndrome was short-lived, followed by relapse of active systemic disease requiring continuous steroid treatment.
This case in some aspects resembles a limited number of other reports of high-dose chemotherapy with autologous progenitor cell support in systemic autoimmunopathies, where although temporary improvement of the autoimmune disease was often obtained, patients usually relapsed later. 6, 7, 14 Recently, a series of five unmanipulated autologous stem cell transplants for different autoimmune diseases was published by the Kiel group and no remissions beyond 1 year were observed. 10 It is only in the group of patients with progressive multiple sclerosis, that a number of long lasting remissions following autologous stem cell transplantations have been observed. 15 This is in contrast with a limited number of reports of allogeneic bone marrow trans-plantation for underlying hematological diseases in the majority of which long-lasting remissions, possibly cures of concomitant autoimmune diseases, mainly rheumatoid arthritis, have been documented. [1] [2] [3] [4] There is, however, one report of the relapse of rheumatoid arthritis 2 years after allogeneic bone marrow transplantation carried out for gold induced aplastic anemia. 16 These reports give rise to the assumption that autologous immune reconstitution rather than the persistence of a recipient-inherent autoantigen may be responsible for the relapse of autoimmune disease after autologous stem cell transplantation. Whether relapses are due to autologous immune reconstitution from immune cells surviving in the patient after high-dose chemotherapy or from immune cells preserved in the transplant, especially in a peripheral blood progenitor cell transplant, remains a matter of debate. The possibility that autoimmune diseases are true stem cell diseases also has to be taken into consideration. 17 If one assumes survival of autoaggressive lymphocyte clones in the patient after autologous transplantation, improvement of the conditioning regimen focusing on immunoablation rather than myeloablation would be required to improve the results in autoimmune disease. In the case presented here, relapse of systemic Sjögren's disease was associated with early dominance of activated T cells in the mononuclear fraction of the patient's peripheral blood and bone marrow. This may point to a possible role for T cell depletion of the autologous graft in order to improve the quality and length of remission after high-dose chemotherapy for autoimmune diseases. Animal studies with marrow transplantation in experimental autoimmune diseases argue in favor of T cell depletion of the graft, [18] [19] [20] and a consensus report from EULAR and EBMT on the use of blood and marrow stem cell transplants in autoimmune diseases is in favor of such a procedure. 21 However, conclusive data on this issue are lacking and clinical studies on autologous progenitor cell transplantation in various autoimmune disorders including the option of graft engineering are warranted.
In conclusion, peripheral blood progenitor cell transplantation for aggressive lymphoma in this patient with systemic Sjögren's disease led to complete remission of the lymphoma, but not to permanent control of the autoimmune disease. Whether there will be a future role for peripheral blood progenitor cell transplantation in the treatment of Sjögren's syndrome needs additional studies. While manipulation of T cell content of the graft and/or conditioning regimen favoring immunoablation appears interesting, their role in improving the response of autoimmune disease remains open.
